Andrew Wasson

Andrew Wasson is a partner in the firm’s New York office, the chair of the firm’s FDA practice, and a member of the Executive Committee. Andrew’s practice involves patent litigation in Federal district court and appellate court proceedings, post-grant patent proceedings, due diligence, and long-term patent portfolio strategy. Andrew’s experience includes pharmaceuticals, biologics, and medical devices in a variety of therapeutic areas (e.g., central nervous system disorders, critical care, ophthalmology, dermatology, oncology, women’s health, and rare diseases) and with a variety of delivery technologies (e.g. extended release, topical, transdermal, injectable, and percutaneous). Currently, Andrew serves as Adjunct Professor of Law at Fordham Law School as well as on the editorial advisory board of the Food & Drug Law Journal.